A Phase I/II Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine in Patients With Metastatic Hormone-Refractory Prostate Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
United States: Food and Drug Administration
G-0010
NCT00140348
December 2001
April 2005
Name | Location |
---|---|
UCSF | San Francisco, California 941430324 |
Fox Chase Cancer Center | Philadelphia, Pennsylvania 19111 |
Carle Cancer Center | Urbana, Illinois 61801 |
Seattle Cancer Care Alliance | Seattle, Washington 98109 |
University of Michigan Medical Center | Ann Arbor, Michigan 48104-0914 |
Emory University | Atlanta, Georgia 30322 |
South Florida Medical Research | Aventura, Florida 33180 |
Northeast Indiana Research | Fort Wayne, Indiana 46804-4128 |
South Orange County Medical Research Center | Laguna Hills, California 92653 |
Urology San Antonio | San Antonio, Texas 78229 |
West Coast Clinical Research | Tarzana, California 91356 |
Virginia Mason Med. Crt. | Seattle, Washington 98101 |